Our Scientists

Associate Professor Mark Hodson

Associate Professor Mark Hodson is a biochemist and has been actively engaged in metabolomics- and biomarker-based research, consultancy and management since 2000, working in roles within industry, consultancy, biotech and academia. He attained a BSc in Biomedical Science with the University Medal from the University of Technology, Sydney, and his doctorate from the Department of Biochemistry, the University of Cambridge. 

Mark was involved in the early application of liquid chromatography-mass spectrometry-based technology to biomarker discovery, drug efficacy and toxicology whilst at GlaxoSmithKline (GSK) in the UK, working closely with leading instrument manufacturers on method and software development. Thereafter he was founding Director of a metabolomics-focused consultancy company (MetaPro), consulting as metabolomics experts to GSK as well as to Roche and the Innomed Predictive Toxicology Project (EU FP6).

Mark was then recruited as Director at Biocrates Life Sciences AG (Austria), providing metabolomics, biomarker and industry expertise, and leading and directing the Contract Research department. In 2011, Mark took up a role as manager of the Metabolomics Australia Node at the University of Queensland, enabling more than 1000 projects from more than 100 collaborators/customers as part of the NCRIS-funded Bioplatforms Australia network.

Mark joined the Victor Chang Cardiac Research Institute in 2017 as Head of Metabolomics within the Victor Chang Innovation Centre. He has successfully supervised three conferred doctoral students and currently supervises three candidates, and has published more than 30 peer-reviewed articles/book chapters during the past five years.

Metabolomics Laboratory

Back To Top